Computer Tool Reads Kidney Scans to Judge Kidney Cancer Spread
Tests a computer scan-reading tool to tell early from advanced kidney cancer in adults.
Key facts
- Who runs it
- Peking University First Hospital
- Where
- Beijing, ChinaSee the site
- Trial code
- Registry title
- Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT
- Status
- Recruiting
- People taking part
- 1,000 people, planned
- Started
- 1 Sept 2024
- Expected to end
- 1 Dec 2027
- Type of study
- Observational
- Record updated
- 10 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for adults with kidney cancer (renal cell carcinoma) confirmed after surgery, who had a good-quality contrast CT scan before surgery.
- Age
- 18 to 85 years
- Sex
- All sexes can join
- Disease stage
- Renal cell carcinoma with a stage after surgery of pT1a-T2b or pT3a
- Earlier treatment
- Must have had surgery, with the removed tissue examined under the microscope. No other earlier treatment is named.
Main reasons for not taking part
- A cancer type other than renal cell carcinoma
- CT images with severe artifacts
- CT scan not done at this institution with slices of 1 mm or thinner
- Incomplete CT image files
- CT image quality not good enough for analysis
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Histopathologically confirmed renal cell carcinoma on postoperative specimen
- Preoperative contrast-enhanced CT performed at our institution with slice thickness ≤ 1 mm and complete DICOM datasets
- Postoperative pathologic staging clearly defined as pT1a-T2b or pT3a
- CT image quality deemed adequate for analysis
Who cannot take part
- 1. Pathologic subtype other than RCC. 2. Images with severe artifacts
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Where in China
- Peking University First Hospital, Beijing,Beijing, ChinaContact: Peking University First Hospital Peking University First HospitalTaking people
About the trial
What the trial wants to find out
This study aims to develop and validate a contrast-enhanced CT-based deep-learning model for automatic and accurate preoperative discrimination between T1-T2 and T3 renal cell carcinoma. By quantifying the model's diagnostic performance on an independent test set-using AUC, sensitivity, specificity, positive/negative predictive values, and decision-curve analysis-we will establish a decision-support tool that can be seamlessly integrated into clinical PACS, thereby reducing staging errors, refining surgical planning, and improving patient outcomes.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT
- Plain-language title
- Computer Tool Reads Kidney Scans to Judge Kidney Cancer SpreadGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07166445, who can take part
- Record updated
- 10 September 2025